Evidence map›Paper›PMID 39392508›Full record

ArticleVirchows Archiv : an international journal of pathology2024

Uterine mesenchymal tumours harboring the KAT6B/A::KANSL1 gene fusion represent a distinct type of uterine sarcoma based on DNA methylation profiles.

Felix K F Kommoss, Alphonse Charbel, David L Kolin, Brooke E Howitt, Martin Köbel, Jen-Chieh Lee, W Glenn McCluggage, Abbas Agaimy, Brendan C Dickson, Andreas von Deimling and 1 more

Abstract read
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Gynecologic oncology reports · 2026
    Article
  2. Uterine sarcoma with KAT6B/A::KANSL1 fusion: an evolving entity.Virchows Archiv : an international journal of pathology · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Felix K F KommossInstitute of Pathology, Heidelberg University Hospital, Heidelberg, Germany. felix.kommoss@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0003-0876-9087
Alphonse CharbelInstitute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
David L KolinDivision of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Brooke E HowittDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Martin KöbelDepartment of Laboratory Medicine and Pathology, University of Calgary, Calgary, AB, Canada.
Jen-Chieh LeeDepartment and Graduate Institute of Pathology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
W Glenn McCluggageDepartment of Pathology, Belfast Health and Social Care Trust, Belfast, UK.
Abbas AgaimyDepartment of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Brendan C DicksonDepartment of Pathology and Laboratory Medicine, Sinai Health System and University of Toronto, Toronto, ON, Canada.
Andreas von DeimlingDepartment of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany.
Cheng-Han LeeDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada. chlee2@ualberta.ca.

Funding

Deutsche Forschungsgemeinschaft 523898075
6 · The paper itself

Abstract

Uterine mesenchymal tumours harboring KAT6B/A::KANSL1 gene fusions typically exhibit histological and immunophenotypic overlap with endometrial stromal and smooth muscle tumours. To date it remains uncertain whether such neoplasms should be regarded as variants of smooth muscle or endometrial stromal neoplasm, or if they constitute a distinct tumour type. In this study we investigated DNA methylation patterns and copy number variations (CNVs) in a series of uterine tumours harboring KAT6B/A::KANSL1 gene fusions in comparison to other mesenchymal neoplasms of the gynecological tract. Unsupervised hierarchical clustering and t-SNE analysis of DNA methylation data (Illumina EPIC array) identified a distinct cluster for 8/13 KAT6B/A::KANSL1 tumours (herein referred to as core cluster). The other 5 tumours (herein referred to as outliers) did not assign to the core cluster but clustered near various other tumour types. CNV analysis did not identify significant alterations in the core cluster. In contrast, various alterations, including deletions at the CDKN2A/B and NF1 loci were identified in the outlier group. Analysis of the DNA methylation clusters in relation to histological features revealed that while tumours in the core KAT6B/A::KANSL1 cluster were histologically bland, outlier tumours frequently exhibited "high-grade" histologic features in the form of significant nuclear atypia, increased mitotic activity and necrosis. Three of the five patients with outlier tumours died from their disease while clinical follow-up in the remaining two patients was limited (less than 12 months). In comparison, none of the 7 out of 8 patients with tumors in the core KAT6B/A::KANSL1 sarcoma cluster, where follow-up was available, died from disease. Furthermore, only 1 out of 7 patients recurred (mean follow-up of 30 months). In conclusion, KAT6B/A::KANSL1 uterine sarcoma is a molecularly unique type of uterine tumour that should be recognized as a distinct entity. These tumors typically exhibit low-grade histologic features but are occasionally morphologically high-grade; the latter have a DNA methylation profile different from the typical low-grade neoplasms and may be associated with aggressive behaviour.

Indexed as

DNA MethylationSarcomaUterine NeoplasmsAdultAgedDNA Copy Number VariationsFemaleHistone AcetyltransferasesHumansMiddle AgedNuclear ProteinsOncogene Proteins, FusionHistone AcetyltransferasesKAT6B protein, humanNSL1 protein, humanNuclear ProteinsOncogene Proteins, FusionDNA methylationKANSL1KAT6B/AUterine sarcoma

Identifiers

PMID39392508
PMCPMC11564218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.